This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BOOK BY MIDNIGHT OCTOBER 29 TO SAVE $400!

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Eric Vivier, Ph.D.
SVP and Chief Scientific Officer at Innate Pharma

Profile

Eric Vivier, DVM, PhD, is Professor of Immunology at Aix-Marseille University and at the Public Hospital of Marseille (AP-HM). In addition, he was appointed in 2018, Scientific Director of Innate Pharma, a biotechnology company dedicated to improving cancer treatment with innovative therapeutic antibodies that exploit the immune system.


He completed his post-doctoral training at Harvard Medical School, then joined Aix-Marseille University as professor at the Centre d'Immunologie de Marseille-Luminy (CIML) in 1993 before becoming its director from 2008 to 2017. He is also one of the founders of Marseille-Immunopo^le, an immunology cluster created in 2014 linking fundamental and therapeutic research, innovation and industrial development on the Aix-Marseille metropole.


Eric Vivier's work focuses on innate immunity and in particular Natural killer and other innate lymphoid cells, at Ciml, at AP-HM and at Innate-Pharma. Professor Vivier has published over 380 scientific articles and is on the list of the most cited researchers: (https://publons.com/researcher/2825347/eric-vivier/ & Google Scholar<https://scholar.google.com/citations?user=NlmFOgMAAAAJ&hl=en>)


A laureate of the European Research Council (ERC advanced grants), a member of the EMBO, the Acade´mie Nationale de Me´decine and the Institut Universitaire de France, Prof. Vivier has received several awards including those from the Ligue Nationale contre le Cancer (1996, 2004 and 2013) and the European Federation of Immunological Societies (EFIS, 2004).


Agenda Sessions

  • Natural Killer Cell Engagers in Cancer Immunotherapy: Next Generation of Immuno-oncology Treatments

    2:15pm